+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Monoamine Oxidase Inhibitors Drugs Market - Global Forecast 2025-2030- Product Image
Monoamine Oxidase Inhibitors Drugs Market - Global Forecast 2025-2030- Product Image
Sale

Monoamine Oxidase Inhibitors Drugs Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 194 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6139935
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The monoamine oxidase inhibitors (MAOIs) market is undergoing pivotal transformation, with innovation and regulatory shifts redefining drug development, commercialization, and operational strategies across neuropsychiatric and neurodegenerative therapies.

Market Snapshot: Monoamine Oxidase Inhibitors

The monoamine oxidase inhibitors market demonstrates steady expansion, driven by evolving clinical practices, the shift toward precision medicine, and dual utility in depression and Parkinson’s disease management. Market stakeholders witness increased traction for optimized formulations and patient-centric approaches, reflecting the sector’s sustained momentum within the global pharmaceutical landscape.

Scope & Segmentation of the MAOIs Market

This report analyzes the comprehensive landscape of monoamine oxidase inhibitor therapies, focusing on segmentation by clinical and commercial attributes. Insights span across innovations, regulatory landscapes, and geographic variations that shape market opportunities.

  • Indication: Major Depressive Disorder (including Atypical Depression and Treatment Resistant Depression), Parkinson’s Disease (Advanced Stage and Early Stage)
  • Molecule Type: Non-Selective MAO Inhibitors (Isocarboxazid, Phenelzine, Tranylcypromine), Selective MAO-B Inhibitors (Rasagiline, Safinamide, Selegiline)
  • Route of Administration: Oral, Transdermal
  • End User: Hospitals, Online Pharmacies, Retail Pharmacies, Specialty Clinics (Neurology Clinics, Psychiatry Clinics)
  • Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
  • Formulation: Capsule, Patch, Tablet
  • Regions: Americas (United States: California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada; Mexico; Brazil; Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Key Companies: Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Viatris Inc., Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy's Laboratories Ltd., Hetero Drugs Limited, Apotex Inc., Bausch Health Companies Inc.

Key Takeaways for Senior Decision-Makers

  • Precision medicine is enhancing patient stratification, particularly via selective MAO-B inhibitors, which play a pivotal role in Parkinson’s disease management.
  • Formulation advances such as transdermal and extended-release formats are improving adherence and reducing side effects, transitioning away from conventional oral regimens.
  • Digital health tools, including remote monitoring and telemedicine, are facilitating real-time therapeutic adjustments, supporting individualized dosing and safety oversight.
  • The competitive landscape is shaped by strategic alliances—collaborations between biotechs, academic centers, and contract manufacturers are accelerating trials and market access.
  • Regional market expansion is influenced by healthcare policy, pricing strategies, and the degree of generic penetration, particularly in emerging economies and areas with evolving regulatory pathways.

Tariff Impact: U.S. Pharmaceutical Policy and MAOIs Supply Chain

The 2025 U.S. pharmaceutical tariffs significantly affect the MAOIs market by increasing input costs and placing pressure on manufacturing and procurement processes. In response, companies pursue nearshoring of active pharmaceutical ingredient (API) production, renegotiate international supply agreements, and revise pricing models. Evolving customs protocols are accelerating investment in resilient logistics and cold chain solutions, especially for formulations requiring strict handling.

Methodology & Data Sources

This research integrates data from peer-reviewed sources, clinical trial registries, regulatory filings, industry reports, and primary interviews with thought leaders and operational executives. Rigorous triangulation and quantitative modeling ensure reliable scenario analysis and risk assessment, validating disruptive trends and operational challenges.

Why This Report Matters

  • Enables informed R&D and commercialization prioritization by mapping segmentation and identifying emerging growth drivers across MAOIs market sub-sectors.
  • Prepares senior leadership to anticipate tariff and regulatory impacts on supply continuity, optimizing both risk mitigation and patient access strategies.
  • Supports decision-making with evidence-based insights into regional dynamics, competitive positioning, and the integration of digital technologies.

Conclusion

The monoamine oxidase inhibitors market is progressing amid clinical advances, operational disruptions, and shifting competitive dynamics. This report equips stakeholders to align strategies with evolving trends and capture new opportunities with clarity and precision.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rapid growth of off-label MAOI prescriptions for treatment resistant depression and anxiety management
5.2. Approval and commercialization of reversible MAO-B inhibitors for neuroprotective therapy in early stage Parkinsons disease
5.3. Emergence of transdermal phenelzine formulations to enhance patient adherence and minimize dietary restrictions
5.4. Patent expirations enabling low cost generic tranylcypromine entry in Latin American and Asia Pacific markets
5.5. Integration of wearable digital adherence monitoring systems with MAOI therapy for improved dietary compliance tracking
5.6. Investments in microdosing protocols combining MAOIs and SSRIs to reduce hypertensive crisis risk and improve tolerability
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Monoamine Oxidase Inhibitors Drugs Market, by Indication
8.1. Introduction
8.2. Major Depressive Disorder
8.2.1. Atypical Depression
8.2.2. Treatment Resistant Depression
8.3. Parkinson's Disease
8.3.1. Advanced Stage
8.3.2. Early Stage
9. Monoamine Oxidase Inhibitors Drugs Market, by Molecule Type
9.1. Introduction
9.2. Non-Selective MAO Inhibitors
9.2.1. Isocarboxazid
9.2.2. Phenelzine
9.2.3. Tranylcypromine
9.3. Selective MAO-B Inhibitors
9.3.1. Rasagiline
9.3.2. Safinamide
9.3.3. Selegiline
10. Monoamine Oxidase Inhibitors Drugs Market, by Route of Administration
10.1. Introduction
10.2. Oral
10.3. Transdermal
11. Monoamine Oxidase Inhibitors Drugs Market, by End User
11.1. Introduction
11.2. Hospitals
11.3. Online Pharmacies
11.4. Retail Pharmacies
11.5. Specialty Clinics
11.5.1. Neurology Clinics
11.5.2. Psychiatry Clinics
12. Monoamine Oxidase Inhibitors Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Monoamine Oxidase Inhibitors Drugs Market, by Formulation
13.1. Introduction
13.2. Capsule
13.3. Patch
13.4. Tablet
14. Americas Monoamine Oxidase Inhibitors Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Monoamine Oxidase Inhibitors Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Monoamine Oxidase Inhibitors Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Pfizer Inc.
17.3.2. Teva Pharmaceutical Industries Ltd.
17.3.3. Sandoz International GmbH
17.3.4. Viatris Inc.
17.3.5. Sun Pharmaceutical Industries Ltd.
17.3.6. Lupin Limited
17.3.7. Dr. Reddy's Laboratories Ltd.
17.3.8. Hetero Drugs Limited
17.3.9. Apotex Inc.
17.3.10. Bausch Health Companies Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. MONOAMINE OXIDASE INHIBITORS DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. MONOAMINE OXIDASE INHIBITORS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. MONOAMINE OXIDASE INHIBITORS DRUGS MARKET: RESEARCHAI
FIGURE 28. MONOAMINE OXIDASE INHIBITORS DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 29. MONOAMINE OXIDASE INHIBITORS DRUGS MARKET: RESEARCHCONTACTS
FIGURE 30. MONOAMINE OXIDASE INHIBITORS DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ATYPICAL DEPRESSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ATYPICAL DEPRESSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY TREATMENT RESISTANT DEPRESSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY TREATMENT RESISTANT DEPRESSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY EARLY STAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY NON-SELECTIVE MAO INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY NON-SELECTIVE MAO INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ISOCARBOXAZID, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ISOCARBOXAZID, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY PHENELZINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY PHENELZINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY TRANYLCYPROMINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY TRANYLCYPROMINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY NON-SELECTIVE MAO INHIBITORS, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY NON-SELECTIVE MAO INHIBITORS, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SELECTIVE MAO-B INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SELECTIVE MAO-B INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY RASAGILINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY RASAGILINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SAFINAMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SAFINAMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SELEGILINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SELEGILINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SELECTIVE MAO-B INHIBITORS, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SELECTIVE MAO-B INHIBITORS, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY NEUROLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY NEUROLOGY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY PSYCHIATRY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY PSYCHIATRY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY PATCH, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY PATCH, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY NON-SELECTIVE MAO INHIBITORS, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY NON-SELECTIVE MAO INHIBITORS, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SELECTIVE MAO-B INHIBITORS, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SELECTIVE MAO-B INHIBITORS, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY NON-SELECTIVE MAO INHIBITORS, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY NON-SELECTIVE MAO INHIBITORS, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SELECTIVE MAO-B INHIBITORS, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SELECTIVE MAO-B INHIBITORS, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 135. CANADA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 136. CANADA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 137. CANADA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2024 (USD MILLION)
TABLE 138. CANADA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2025-2030 (USD MILLION)
TABLE 139. CANADA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2024 (USD MILLION)
TABLE 140. CANADA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, 2025-2030 (USD MILLION)
TABLE 141. CANADA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 142. CANADA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 143. CANADA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY NON-SELECTIVE MAO INHIBITORS, 2018-2024 (USD MILLION)
TABLE 144. CANADA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY NON-SELECTIVE MAO INHIBITORS, 2025-2030 (USD MILLION)
TABLE 145. CANADA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SELECTIVE MAO-B INHIBITORS, 2018-2024 (USD MILLION)
TABLE 146. CANADA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SELECTIVE MAO-B INHIBITORS, 2025-2030 (USD MILLION)
TABLE 147. CANADA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 148. CANADA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 149. CANADA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. CANADA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. CANADA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 152. CANADA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 153. CANADA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 154. CANADA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 155. CANADA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 156. CANADA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 157. MEXICO MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 158. MEXICO MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 159. MEXICO MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2024 (USD MILLION)
TABLE 160. MEXICO MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2025-2030 (USD MILLION)
TABLE 161. MEXICO MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2024 (USD MILLION)
TABLE 162. MEXICO MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, 2025-2030 (USD MILLION)
TABLE 163. MEXICO MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 164. MEXICO MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 165. MEXICO MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY NON-SELECTIVE MAO INHIBITORS, 2018-2024 (USD MILLION)
TABLE 166. MEXICO MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY NON-SELECTIVE MAO INHIBITORS, 2025-2030 (USD MILLION)
TABLE 167. MEXICO MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SELECTIVE MAO-B INHIBITORS, 2018-2024 (USD MILLION)
TABLE 168. MEXICO MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SELECTIVE MAO-B INHIBITORS, 2025-2030 (USD MILLION)
TABLE 169. MEXICO MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 170. MEXICO MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 171. MEXICO MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 172. MEXICO MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 173. MEXICO MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 174. MEXICO MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 175. MEXICO MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. MEXICO MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. MEXICO MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 178. MEXICO MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 187. BRAZIL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY NON-SELECTIVE MAO INHIBITORS, 2018-2024 (USD MILLION)
TABLE 188. BRAZIL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY NON-SELECTIVE MAO INHIBITORS, 2025-2030 (USD MILLION)
TABLE 189. BRAZIL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SELECTIVE MAO-B INHIBITORS, 2018-2024 (USD MILLION)
TABLE 190. BRAZIL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SELECTIVE MAO-B INHIBITORS, 2025-2030 (USD MILLION)
TABLE 191. BRAZIL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 192. BRAZIL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 193. BRAZIL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 197. BRAZIL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. BRAZIL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 201. ARGENTINA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 202. ARGENTINA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 203. ARGENTINA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2024 (USD MILLION)
TABLE 204. ARGENTINA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, 2025-2030 (USD MILLION)
TABLE 207. ARGENTINA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 208. ARGENTINA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 209. ARGENTINA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY NON-SELECTIVE MAO INHIBITORS, 2018-2024 (USD MILLION)
TABLE 210. ARGENTINA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY NON-SELECTIVE MAO INHIBITORS, 2025-2030 (USD MILLION)
TABLE 211. ARGENTINA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SELECTIVE MAO-B INHIBITORS, 2018-2024 (USD MILLION)
TABLE 212. ARGENTINA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SELECTIVE MAO-B INHIBITORS, 2025-2030 (USD MILLION)
TABLE 213. ARGENTINA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 214. ARGENTINA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 215. ARGENTINA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. ARGENTINA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. ARGENTINA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 218. ARGENTINA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 219. ARGENTINA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 220. ARGENTINA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 221. ARGENTINA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 222. ARGENTINA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2024 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2025-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2024 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, 2025-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY NON-SELECTIVE MAO INHIBITORS, 2018-2024 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY NON-SELECTIVE MAO INHIBITORS, 2025-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SELECTIVE MAO-B INHIBITORS, 2018-2024 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SELECTIVE MAO-B INHIBITORS, 2025-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 247. UNITED KINGDOM MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 248. UNITED KINGDOM MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 249. UNITED KINGDOM MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2024 (USD MILLION)
TABLE 250. UNITED KINGDOM MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2025-2030 (USD MILLION)
TABLE 251. UNITED KINGDOM MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2024 (USD MILLION)
TABLE 252. UNITED KINGDOM MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, 2025-2030 (USD MILLION)
TABLE 253. UNITED KINGDOM MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 254. UNITED KINGDOM MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 255. UNITED KINGDOM MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY NON-SELECTIVE MAO INHIBITORS, 2018-2024 (USD MILLION)
TABLE 256. UNITED KINGDOM MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY NON-SELECTIVE MAO INHIBITORS, 2025-2030 (USD MILLION)
TABLE 257. UNITED KINGDOM MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SELECTIVE MAO-B INHIBITORS, 2018-2024 (USD MILLION)
TABLE 258. UNITED KINGDOM MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SELECTIVE MAO-B INHIBITORS, 2025-2030 (USD MILLION)
TABLE 259. UNITED KINGDOM MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 260. UNITED KINGDOM MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 261. UNITED KINGDOM MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 262. UNITED KINGDOM MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 263. UNITED KINGDOM MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 264. UNITED KINGDOM MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 265. UNITED KINGDOM MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. UNITED KINGDOM MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 267. UNITED KINGDOM MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 268. UNITED KINGDOM MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 269. GERMANY MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 270. GERMANY MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 271. GERMANY MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2018-2024 (USD MILLION)
TABLE 272. GERMANY MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, 2025-2030 (USD MILLION)
TABLE 273. GERMANY MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2024 (USD MILLION)
TABLE 274. GERMANY MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, 2025-2030 (USD MILLION)
TABLE 275. GERMANY MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 276. GERMANY MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 277. GERMANY MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY NON-SELECTIVE MAO INHIBITORS, 2018-2024 (USD MILLION)
TABLE 278. GERMANY MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY NON-SELECTIVE MAO INHIBITORS, 2025-2030 (USD MILLION)
TABLE 279. GERMANY MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SELECTIVE MAO-B INHIBITORS, 2018-2024 (USD MILLION)
TABLE 280. GERMANY MONOAMINE OXIDASE INHIBITORS DRUGS MARKET SIZE, BY SELECTIVE MAO-B INHIBITORS, 2025-2030 (US

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Monoamine Oxidase Inhibitors Drugs market report include:
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Viatris Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Limited
  • Dr. Reddy's Laboratories Ltd.
  • Hetero Drugs Limited
  • Apotex Inc.
  • Bausch Health Companies Inc.

Related Topics

Related Reports

Monoamine Oxidase Inhibitors - Pipeline Insight, 2025 - Product Image

Monoamine Oxidase Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Monoamine Oxidase B (MAO-B) Inhibitor - Pipeline Insight, 2025 - Product Image

Monoamine Oxidase B (MAO-B) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Xanthine Oxidase Inhibitors for the Treatment of Hyperuricemia Market - Global Forecast 2025-2030 - Product Image

Xanthine Oxidase Inhibitors for the Treatment of Hyperuricemia Market - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
Xanthine Oxidase Inhibitor Market - Product Image

Xanthine Oxidase Inhibitor Market

  • Report
  • 250 Pages
  • Global
From
Bilirubin Oxidase Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Bilirubin Oxidase Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.